Cancer care in Mexico is being pushed to its limits—but also quietly transformed.
Mexico’s National Institute of Cancerology (INCan) is celebrating 79 years of service while stepping up its role as a central pillar of the country’s cancer care system, especially for complex cases that other hospitals cannot manage. The institute currently attends around 7% of all cancer patients in Mexico and has seen sharp increases in breast, prostate, and cervical cancer services between 2018 and 2024, driven by rising demand and major investments in technology, training, and infrastructure.
INCan’s leadership frames this anniversary not just as a celebration, but as a serious obligation to sustain nearly eight decades of care, research, and specialist training. According to Director General Óscar Arrieta, the institute has continued to expand its reach despite mounting pressure on staff and systems that comes with being a national referral center for high‑complexity oncology cases. He emphasizes that the mission now is to safeguard what has been built while adapting to new clinical and epidemiological challenges.
Arrieta underscores that 79 years of history translate into a commitment to continue improving care, strengthening research, and training new generations of oncology professionals. The institute’s priorities include expanding access for patients across the country, upgrading medical equipment, and integrating innovations that help doctors make more precise decisions and improve survival and quality of life. But here’s where it gets controversial: can a single institution carry so much of the country’s most complex cancer burden without broader systemic reform?
Data reported by INCan reveal how dramatically demand has grown. From 2018 to 2024, breast cancer care surged by 146%, prostate cancer cases by 89%, and cervical cancer cases by 56%, reflecting both the high prevalence of these tumors and the institute’s role as a last‑resort center for difficult cases. In 2024 alone, INCan provided about 318,000 consultations across oncology specialties, a number that illustrates the intense workload shouldered by medical, nursing, technical, and administrative teams who must balance volume with quality.
Looking to 2025, the institute anticipates registering more than 8,300 new patients for first‑time care, a figure that will only increase pressure on services and waiting times. INCan views this as a chance to double down on early‑detection initiatives and faster referral routes, particularly for cancers where late diagnosis dramatically increases the risk of death. Researcher Gabriela Torres of the National Institute of Public Health argues that, to genuinely reduce breast cancer mortality, at least 60% of cases should be detected in stages I or II and no more than 60 days should pass between a woman’s first consultation and her histopathological diagnosis—a timeline that many health systems struggle to meet in practice.
A key pillar of INCan’s response has been technological modernization. Among the most notable additions is stereotactic radiosurgery and stereotactic radiotherapy, implemented in October with an initial focus on skin cancer and cutaneous lesions. This high‑precision technique allows doctors to target tumors more accurately while limiting damage to nearby healthy tissues, which can translate into fewer side effects and better functional outcomes. And this is the part most people miss: behind every new machine is a need for highly trained staff, maintenance, and sustainable financing—issues that are rarely visible to the public.
In August 2024, INCan also began using robotic surgery systems to expand minimally invasive surgical options for eligible patients. These technologies aim to shorten hospital stays, lower the risk of complications, and reduce treatment toxicity by allowing more delicate, precise interventions. Both the radiosurgery and robotic platforms fit into a broader roadmap to renew diagnostic and therapeutic tools, with future plans that include upgrading PET‑CT scanners and other imaging equipment critical for accurate staging and treatment planning.
Education and training remain at the heart of INCan’s identity. The institute currently maintains 68 active agreements with universities and academic institutions in Mexico and abroad, reflecting its role as a teaching hospital and a hub for oncology expertise. Of these, 55 agreements support undergraduate training with around 210 students, while 13 focus on postgraduate education and back more than 450 medical residents who rotate through various specialties.
Arrieta points out that one of INCan’s strengths is its commitment to translational models that connect laboratory research with real‑world clinical practice. By tightly linking basic science, clinical trials, and patient care, the institute has boosted the development of diagnostic tools, targeted therapies, and prevention strategies that can move more quickly from research bench to bedside. This integration is seen as essential not only for improving patient outcomes, but also for maintaining scientific rigor and positioning Mexico as a serious player in oncology research.
Since 2022, INCan has been operating under a gratuity model that covers surgery, radiotherapy, and medications for eligible patients, including access to targeted therapies, molecular testing, and immunotherapy. This approach is designed to reduce financial barriers that often push families into debt or force them to abandon treatment midway. At the same time, the institute recognizes that comprehensive cancer care goes beyond drugs and procedures, and it is prioritizing the growth of supportive services such as mental health, nutritional counseling, and rehabilitation to address patients’ broader physical and emotional needs.
Prevention and early detection also feature prominently in INCan’s long‑term vision. One flagship initiative is the DETECTO program, which focuses on early identification of lung cancer using low‑dose CT scans. By detecting tumors at earlier stages—often before symptoms appear—the program has demonstrated its potential to intercept cases that would otherwise be diagnosed late, when treatment options are more limited and survival is lower. As a result, DETECTO is emerging as a reference model for lung cancer screening programs across Latin America.
Looking ahead, the institute plans to expand access to innovative oncology drugs, increase radiotherapy capacity, and harness digital tools to refine diagnosis and improve patient comfort and experience. Digital technologies—such as advanced imaging software, decision‑support systems, and better electronic records—could help clinicians manage growing patient volumes while maintaining safety and consistency of care. But here’s where it gets controversial: Can technology and institutional effort alone offset broader structural gaps in Mexico’s health system, or is a deeper rethinking of national cancer policy needed?
INCan’s challenge for the coming years will be to balance rapid growth in patient numbers with the promise of personalized, humane, and timely care. As it celebrates 79 years, the institute stands at a crossroads between consolidation and transformation—caught between the weight of tradition and the urgency of modern oncology demands.
What do you think: Is it fair for one institution to carry such a large share of Mexico’s most complex cancer cases, or should the country redistribute capacity and investment across more centers? Do you agree that early detection and gratuity‑based models should be the top priorities, or would you rather see even more focus on cutting‑edge technologies like robotics and immunotherapy? Share whether you strongly agree, strongly disagree, or fall somewhere in the middle—and why.
